2. Search Result
Search Result
Results for "

Trastuzumab

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

12

Fluorescent Dyes

2

Biochemical Assay Reagents

8

Peptides

7

Inhibitory Antibodies

1

Isotope-Labeled Compounds

1

Click Chemistry

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9907
    Trastuzumab
    50+ Cited Publications

    Anti-Human HER2, Humanized Antibody

    		 Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody Cancer
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
    Trastuzumab
  • HY-13631E
    Deruxtecan
    20+ Cited Publications

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-138298A
    Trastuzumab deruxtecan
    5 Publications Verification

    T-DXd; DS-8201; DS-8201a

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-138298
    Trastuzumab deruxtecan (solution)
    5 Publications Verification

    T-DXd (solution); DS-8201 (solution); DS-8201a (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-P9921
    Trastuzumab emtansine
    5+ Cited Publications

    Ado-Trastuzumab emtansine; PRO132365; T-DM 1

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine
  • HY-P9907A
    Trastuzumab (anti-HER2)
    50+ Cited Publications

    Anti-Human HER2, Humanized Antibody (anti-HER2)

    		 ADC Antibody EGFR Cancer
    Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
    Trastuzumab (anti-HER2)
  • HY-P9921A
    Trastuzumab emtansine (solution)
    Maximum Cited Publications
    6 Publications Verification

    Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine (solution)
  • HY-164992
    Trastuzumab vedotin
    2 Publications Verification

    MRG002; Trastuzumab MMAE

    		 Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
    Trastuzumab vedotin
  • HY-W087187
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Infection Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .
    DOTAGA-anhydride
  • HY-129589
    Thailanstatin A
    2 Publications Verification

    		 ADC Payload Cancer
    Thailanstatin A is an ultra-potent inhibitor of eukaryotic RNA splicing (IC50=650 nM). Thailanstatin A exerts effects via non-covalent binding to the SF3b subunit of the U2 snRNA subcomplex of the spliceosome and shows low-nM to sub-nM IC50s against multiple cancer cell lines. Thailanstatin A, a payload for ADCs, is conjugated to the lysines on trastuzumab yielding “linker-less” ADC .
    Thailanstatin A
  • HY-P99547
    Trastuzumab duocarmazine

    (vic)-Trastuzumab duocarmazine

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .
    Trastuzumab duocarmazine
  • HY-153263
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC .
    (Aminooxy)acetamide-Val-Cit-PAB-MMAE
  • HY-13631EG
    Deruxtecan

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan (GMP) (MC-GGFG-DXD (GMP)) is Deruxtecan (HY-13631E) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan (HY-138298A) and Patritumab deruxtecan (HY-P99813) .
    Deruxtecan
  • HY-145102
    NCT-58

    		HSP Apoptosis Cancer
    NCT-58 is a potent inhibitor of C-terminal HSP90. NCT-58 does not induce the heat shock response (HSR) due to its targeting of the C-terminal region and elicits anti-tumor activity via the simultaneous downregulation of HER family members as well as inhibition of Akt phosphorylation. NCT-58 kills Trastuzumab-resistant breast cancer stem-like cells. NCT-58 induces apoptosis in HER2-positive breast cancer cells .
    NCT-58
  • HY-176415
    Cys-MC-GGFG-Dxd

    		Drug-Linker Conjugates for ADC Cancer
    Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
    Cys-MC-GGFG-Dxd
  • HY-164762
    Trastuzumab rezetecan

    SHR-A1811

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab rezetecan (SHR-A1811) is a HER2-targeting antibody-drug conjugate (ADC). Trastuzumab rezetecan is composed of a humanized anti-HER2 antibody (HY-P9907), a cleavable linker MC-Gly-Gly-Phe-Gly (HY-44246), and a topoisomerase I inhibitor payload Rezetecán (HY-147408). Trastuzumab rezetecan can be used for research in HER2-positive breast cancer .
    Trastuzumab rezetecan
  • HY-150074
    STING agonist-18

    		STING ADC Payload Cancer
    STING agonist-18 (compound 1a) is a STING agonist that can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .
    STING agonist-18
  • HY-163099
    P5(PEG24)-VC-PAB-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Apoptosis Cancer
    P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
    P5(PEG24)-VC-PAB-Exatecan
  • HY-147408
    Rezetecan

    SHR9265

    		 Topoisomerase ADC Payload Cancer
    Rezetecan (SHR9265) is a topoisomerase I inhibitor. In addition, Rezetecan can be used to synthesize Trastuzumab rezetecan, an antineoplastic agent. Rezetecán can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs) .
    Rezetecan
  • HY-130426
    Maleimido-tri(ethylene glycol)-propionic acid

    Mal-PEG3-acid

    		 ADC Linker PROTAC Linkers Cancer
    Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-specific cysteine mutant trastuzumab-A114C conjugation . Maleimido-tri(ethylene glycol)-propionic acid also can be used as a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
    Maleimido-tri(ethylene glycol)-propionic acid
  • HY-160015
    CB07-Exatecan

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    CB07-Exatecan is an ADC drug-Linker conjugate that can be used for the synthesis of ADCs. ADC conjugated with CB07-Exatecan and trastuzumab inhibits the growth of HER2-positive cancer cells. CB07-Exatecan can be used in cancer research .
    CB07-Exatecan
  • HY-156991
    NODAGA-NHS

    NODA-GA-NHS ester

    		 EGFR Radionuclide-Drug Conjugates (RDCs) Cancer
    NODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate 64Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [ 64Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma .
    NODAGA-NHS
  • HY-P991588
    HLX-22

    AC101

    		 EGFR Apoptosis Cancer
    HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
    HLX-22
  • HY-161781
    HVH-2930

    		HSP EGFR Akt Survivin Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer .
    HVH-2930
  • HY-D2309
    IRDye700Dx (Maleimide)

    		Fluorescent Dye Photosensitizer Cancer
    IRDye700Dx Maleimide is a Photosensitizer. When conjugated with HER2 Affibody and activated by near-infrared light, IRDye700Dx Maleimide induces death in HER2-positive breast cancer cells without causing damage to HER2-negative breast cancer cells .
    IRDye700Dx (Maleimide)
  • HY-175888
    APL-1082

    Mc-exo-EVC-Exatecan

    		 Drug-Linker Conjugates for ADC Cancer
    APL-1082 is a drug-Linker conjugate that can be used for ADC synthesis. APL-1082 contains Exatecan (HY-13631) and Linker (HY-175929). APL-1082 reduces aggregation and hydrophobicity in Trastuzumab (HY-P9907) ADCs, enables production of high-DAR (10) ADCs with homogeneity and defined physicochemical properties. APL-1082 forms a Trastuzumab ADC with enhanced stability, showing greater DAR retention over time. APL-1082 can be used for the research of gastric cancer .
    APL-1082
  • HY-P3146A
    FTISADTSK acetate

    		Drug Metabolite Cancer
    FTISADTSK acetate is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
    FTISADTSK acetate
  • HY-P3146S
    FTISADTSK-13C6,15N2 TFA

    		Isotope-Labeled Compounds Cancer
    FTISADTSK- 13C6, 15N2 TFA is 13C- and 15N-labeled FTISADTSK (HY-P3146). FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
    FTISADTSK-13C6,15N2 TFA
  • HY-157169
    IBL-302

    AMU302

    		 Pim mTOR Akt PI3K Cancer
    IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629) .
    IBL-302
  • HY-P3147A
    IYPTNGYTR acetate

    		Drug Metabolite Others
    IYPTNGYTR acetate, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR acetate can be used to monitor in vivo Trastuzumab metabolism .
    IYPTNGYTR acetate
  • HY-150074A
    STING agonist-18 diTFA

    		STING ADC Payload Cancer
    STING agonist-18 (compound 1a) diTFA is a STING agonist that can be used for synthesis of antibody-drug conjugates (ADCs), such Trastuzumab (HY-P9907) conjugate .
    STING agonist-18 diTFA
  • HY-E70883
    Endoglycosidase S (D233Q mutant)

    EndoS D233Q

    		 Glycosidase Others
    Endoglycosidase S (D233Q mutant) (EndoS D233Q) is a mutant endoglycosidase, which catalyzes the glycosylation of Trastuzumab (HY-P9907)-GlcNAc with the functionalized, non-natural glycans to give glycosylated monoclonal Abs (mAbs) carrying two glycans each functionalized with two reaction handles .
    Endoglycosidase S (D233Q mutant)
  • HY-172664
    Trabectedin derivative 2

    		Drug Derivative Cancer
    Trabectedin derivative 2 (compound PL-12) is a trabectedin derivative that can be used in research on ovarian cancer, gastric cancer, and breast cancer .
    Trabectedin derivative 2
  • HY-158005
    Anticancer agent 195

    		Apoptosis Cancer
    Anticancer agent 195 (Compound 10) is an inhibitor for ELF3-MED23 PPI with Ki of 0.68 μM. Anticancer agent 195 induces apoptosis and exhibits antitumor activity .
    Anticancer agent 195
  • HY-176559
    LacNAc-VC-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab (HY-P9907) by WT Endo-S2 .
    LacNAc-VC-PAB-MMAE
  • HY-178275
    Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol

    		Drug-Linker Conjugates for ADC Cancer
    Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol (Example 9) is a conjugate of the ADC toxic molecule and the linker, where the toxic molecule part is Hydrotecan (HY-164378), and the linker part is Mc-Glu(D-Glucamine)-val-ala (HY-178309) .
    Hydrotecan-NH-L-Ala-L-Val-L-Gln(CO-C5-succinimide)-D-glucitol
  • HY-172820
    Trastuzumab envedotin

    DP303c

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab envedotin (DP303c) is a anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab envedotin is composed of the tubulin polymerization inhibitor Monomethyl auristatin E (MMAE) (HY-15162) to the anti-HER2 antibody DP001 via a cleavable linker. Trastuzumab envedotin can be used for the research of HER2-positive solid tumors, such as breast cancer, colorectal cancer, and gastric cancer .
    Trastuzumab envedotin
  • HY-151207
    Anticancer agent 81

    		Apoptosis ADC Payload Cancer
    Anticancer agent 81 (Compound 37b3) is an anticancer agent and can induce tumor cell cycle arrest and apoptosis. Anticancer agent 81 can be used as a payload to conjugate with Trastuzumab (HY-P9907) to obtain the antibody–agent conjugate (ADC) T-PBA. T-PBA maintained its mode of target and internalization ability of Trastuzumab .
    Anticancer agent 81
  • HY-130161
    m-PEG4-Br

    		ADC Linker PROTAC Linkers Cancer
    m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab (HY-P9907). m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in vitro potency . m-PEG4-Br also can be used as a PROTAC linker that can be used in the synthesis of PROTACs.
    m-PEG4-Br
  • HY-P11316
    DBCO-tag peptide P1

    		Biochemical Assay Reagents Drug-Linker Conjugates for ADC Others
    DBCO-tag peptide P1 is a cysteine-containing peptide tag. DBCO-tag peptide P1 selectively reacts with dibenzocyclooctyne (DBCO) to yield stable dibenzocyclooctenyl thioethers. DBCO-tag peptide P1 enables site-selective mEGFP labeling and antibody (such as Trastuzumab (HY-P9907)) labelling without impairing the protein binding function. DBCO-tag peptide P1 can be used for ADC synthesis and mEGFP labeling research .
    DBCO-tag peptide P1
  • HY-P3146
    FTISADTSK

    		Drug Metabolite Cancer
    FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM) .
    FTISADTSK
  • HY-P99558
    Timigutuzumab

    GEXMab73; GT-MAb7.3-GEX; Trastuzumab-GEX

    		 EGFR Cancer
    Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
    Timigutuzumab
  • HY-P991582
    BI-1607

    		Fc Receptor (FcR) Cancer
    BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907) .
    BI-1607
  • HY-W731085
    MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH

    		ADC Linker Cancer
    MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH is an ADC linker that can be combined with the cytotoxic Camptothecin (HY-16560) to form an ADC-related drug-linker conjugate (Drug- Linker Conjugates for ADC).MC-GGFG-NH-CH2-O-CH2-cyclopropane-COOH is conjugated to Camptothecin, which can further bind to the antibody Trastuzumab (HY-P9907) to form Antibody-Drug Conjugates (ADCs) .
    MC-GGFG-NH-CH2-O-CH2-(s-cyclopropane)-COOH
  • HY-W087187G
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .
    DOTAGA-anhydride
  • HY-177414
    BB-1701

    		Antibody-Drug Conjugates (ADCs) EGFR Inflammation/Immunology Cancer
    BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune .
    BB-1701
  • HY-P3147
    IYPTNGYTR

    		Drug Metabolite Others
    IYPTNGYTR, a deamidation-sensitive signature peptide, is a deamidation product of Trastuzumab. IYPTNGYTR can be used to monitor in vivo Trastuzumab metabolism .
    IYPTNGYTR
  • HY-W1050525
    Fmoc-Val-Ala-Gly

    		ADC Linker Cancer
    Fmoc-Val-Ala-Gly (compound 58a) is a cleavable ADC linker, can be conjugated to the antibody Trastuzumab (HY-P9907) to form an antibody-drug conjugate (ADC) .
    Fmoc-Val-Ala-Gly
  • HY-148773
    MC-Gly-Gly-Phe-Boc

    		ADC Linker Cancer
    MC-Gly-Gly-Phe-Boc is involved in the synthesis of antibody-drug conjugates (ADCs) to Trastuzumab (HY-P9907). MC-Gly-Gly-Phe-Boc can participate in cancer research .
    MC-Gly-Gly-Phe-Boc
  • HY-49463
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz

    		ADC Linker Neurological Disease
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz is an ADC linker that can be used in the synthesis of ADCs (such as Trastuzumab deruxtecan and U3-1402).
    Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: